NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results

NeuroPace (NASDAQ:NPCE - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.07, Zacks reports. The firm had revenue of $21.47 million during the quarter, compared to analyst estimates of $21.14 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%.

NeuroPace Trading Down 1.6 %

Shares of NASDAQ NPCE traded down $0.18 during midday trading on Friday, hitting $11.00. The company's stock had a trading volume of 271,316 shares, compared to its average volume of 120,418. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The business's 50 day moving average is $12.72 and its two-hundred day moving average is $9.77. NeuroPace has a 12-month low of $5.45 and a 12-month high of $15.77. The firm has a market cap of $328.33 million, a P/E ratio of -11.00 and a beta of 2.06.

Analyst Ratings Changes

A number of research firms have recently weighed in on NPCE. UBS Group began coverage on NeuroPace in a research note on Tuesday, January 21st. They issued a "buy" rating and a $17.00 price objective for the company. Wells Fargo & Company increased their price target on NeuroPace from $13.00 to $17.00 and gave the company an "overweight" rating in a research note on Thursday, January 30th. JPMorgan Chase & Co. increased their price target on NeuroPace from $9.00 to $14.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. Finally, Cantor Fitzgerald upped their price objective on NeuroPace from $19.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, NeuroPace has a consensus rating of "Moderate Buy" and an average price target of $15.20.

Remove Ads

Insider Transactions at NeuroPace

In other NeuroPace news, insider Martha Morrell sold 3,200 shares of the firm's stock in a transaction on Friday, January 24th. The stock was sold at an average price of $15.01, for a total transaction of $48,032.00. Following the transaction, the insider now directly owns 87,062 shares in the company, valued at $1,306,800.62. This trade represents a 3.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Ltd. Kck sold 5,270,845 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,352,479 shares of company stock worth $50,670,217. 22.20% of the stock is currently owned by company insiders.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.